Aclarion Raises $4.7M to Advance AI-Powered Chronic Back Pain Technology
TL;DR
Aclarion, Inc. sold 506,803 shares at $9.25/share, raising $4.7 million in a registered direct offering, providing investors with potential financial growth.
Aclarion's Nociscan utilizes MRS, signal processing, biomarkers, and AI algorithms to pinpoint sources of chronic low back pain for precise treatment optimization.
Aclarion's technology enhances patient care by aiding physicians in identifying the exact location of chronic low back pain, leading to personalized and effective treatment plans.
Aclarion's innovative Nociscan platform blends medical science with AI to revolutionize chronic low back pain diagnosis, showcasing the future of healthcare technology.
Healthcare technology company Aclarion, Inc. (Nasdaq: ACON, ACONW) has announced a $4.7 million registered direct offering of common stock, positioning the company to advance its AI-powered platform for chronic back pain diagnosis. The company will sell 506,803 shares at $9.25 per share, with the transaction expected to close by January 31, 2025.
The funding comes at a crucial time in healthcare technology development, particularly in the field of chronic pain management. Aclarion's flagship product, Nociscan, represents a significant advancement in back pain diagnosis by using Magnetic Resonance Spectroscopy (MRS) and AI algorithms to help physicians differentiate between painful and non-painful spinal discs – a distinction that has traditionally been challenging to make with conventional imaging methods.
This capital injection will support market development, clinical evidence gathering, and product development, potentially accelerating the adoption of more precise diagnostic tools in spine care. For the estimated millions of Americans suffering from chronic back pain, this technology could lead to more targeted and effective treatment strategies by providing physicians with clearer insights into pain sources.
The offering, managed by Dawson James Securities, Inc., is being conducted under a shelf registration statement that received SEC approval in September 2024. This funding round demonstrates growing investor confidence in AI-powered medical diagnostic tools and could signal a shift toward more data-driven approaches in pain management.
Curated from NewMediaWire